PEAK6 Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

PEAK6 Group’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,000	Closed	-$293K	–	5925
2015 Q1	$293K	Sell	3,000 -27,800	-90%	-$2.94M	﹤0.01%	3081
2014 Q4	$2.86M	Sell	30,800 -34,200	-53%	-$2.7M	0.02%	1022
2014 Q3	$4.47M	Buy	65,000 +9,500	+17%	+$680K	0.03%	715
2014 Q2	$5.82M	Buy	55,500 +48,000	+640%	+$4.08M	0.06%	448
2014 Q1	$622K	Buy	+7,500	New	+$694K	0.01%	2339
2013 Q4	–	Sell	-12,600	Closed	-$399K	–	5917
2013 Q3	$399K	Buy	+12,600	New	+$620K	﹤0.01%	3009

PEAK6 Group's GEVA Position: Q2 2015 in Review

PEAK6 Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,515 shares — an estimated $148K sold.

PEAK6 Group first reported a position in GEVA in Q1 2015 and held it in 1 quarter. The position peaked at $148K in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

PEAK6 Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
PEAK6 Group sold 1,515 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $148K.
PEAK6 Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015 and held it in 1 quarter.
PEAK6 Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $148K in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on PEAK6 Group's 13F filing for Q2 2015, filed 11 Aug 2015.